A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Astegolimab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Roche
Most Recent Events
- 14 Jul 2023 Status changed from not yet recruiting to recruiting.
- 15 Jun 2023 Planned initiation date changed from 7 Jun 2023 to 5 Jul 2023.
- 30 May 2023 New trial record